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Abstract
Background: Ischemic stroke in young adults is a major health problem being associated with a higher vascular
morbidity and mortality compared to controls, and a stroke recurrence rate of 25% during the first decade. The
assumed cause of infarction and the detected risk factors determine the early- and long-term treatment. However,
for many patients the cause of stroke remains unknown. Risk factor profile and etiology differ in young and elderly
ischemic stroke patients, and atherosclerosis is the determined underlying condition in 10 to 15%. However,
subclinical atherosclerosis is probably more prevalent and may go unrecognized.
Ultrasound imaging is a sensitive method for the detection of arterial disease and for measurement of adipose
tissue. The relationship between intima-media thickness (IMT), plaques, cardiovascular risk factors including visceral
adipose tissue (VAT) and ischemic events has repeatedly been shown.
We have established The Norwegian Stroke in the Young Study (NOR-SYS) as a three-generation research program
with the goal to increase our knowledge on heredity and the development of arterial disease and ischemic stroke.
Extended standardized ultrasound examinations are done in order to find subclinical vessel disease for early and
better prophylaxis.
Methods/Design: NOR-SYS is a prospective long-term research program. Standardized methods are used for
anamnestic, clinical, laboratory, imaging, and ultrasound data collection in ischemic stroke patients aged ≤60 years,
their partners and joint adult offspring. The ultrasound protocol includes the assessment of intracranial, carotid and
femoral arteries, abdominal aorta, and the estimation of VAT. To date, the study is a single centre study with
approximately 400 patients, 250 partners and 350 adult offspring expected to be recruited at our site.
Discussion: NOR-SYS aims to increase our knowledge about heredity and the development of arterial vascular
disease in young patients with ischemic stroke and their families. Moreover, optimization of diagnostics, prophylaxis
and early intervention are major targets with the intention to reduce stroke recurrence and other clinical arterial
events, physical disability, cognitive impairment and death.
NOR-SYS is reviewed and approved by the Regional Committee for Medical and Health Research Ethics,
Western-Norway (REK-Vest 2010/74), and registered in ClinicalTrials.gov: NCT01597453.
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Background
Cerebrovascular and coronary artery disease are the
main causes of disability and death in the western world
[1]. According to observational studies where TOAST
criteria have been used, atherosclerosis is the underlying
condition in 10 to 15% of patients with ischemic cere-
brovascular events of determined etiology [2]. However,
in 30-40% of cases the cause of stroke remains unknown
[3]. Risk factor profile and etiology differ in young ische-
mic stroke patients compared to the elderly [3-5]. In
addition, young patients have a higher vascular morbid-
ity and mortality compared to healthy controls [6-9],
and recurrent ischemic events are common [10,11]. Fur-
ther, a significant portion of ischemic stroke patients
have unrecognized atherosclerosis not only located to
cervical arteries, but as well to intracranial arteries [12],
to coronary arteries [13], to the aortic arch [14] and to
femoral arteries [15]. As therapeutic options are limited,
primary and secondary prophylaxis of atherosclerosis
and generalized arterial disease should be a major target
with the purpose to reduce long-term disability and
death among young stroke patients.
Ultrasound imaging is a sensitive, non-invasive, and
low-cost method for the detection of arterial vessel disease
in major arteries [16,17]. The measurement of carotid
intima-media thickness (cIMT) and plaques in B-mode
ultrasound has become a tool for vascular risk prediction,
as the relationship between IMT, plaques, cardiovascular
risk factors and future ischemic events has consequently
been shown in several longitudinal studies, predominantly
in older individuals [17-27]. However, the value of IMT
measurements in all carotid artery segments compared
with measurements in the distal CCA alone is disputable
[28], and a recent meta-analysis concluded that cIMT
measurements in the CCA alone adds little to the im-
provement of a 10-year risk prediction [29].
NOR-SYS is a concept for the standardized gathering
of anamnestic, clinical and biological data in young is-
chemic stroke patients, their partners, and their family
members. The intention is to estimate the presence of
arterial vessel disease, to determine the individual’s vas-
cular risk profile, and to offer optimal prevention.
Inclusion of the patients’ partners and joint adult off-
spring is providing a platform for primary vascular pre-
vention and early intervention. Stroke is a result of
multifactorial causes with genetic, environmental and
life-style components [30]. The combination of a stan-
dardized case-history, standardized ultrasound protocols,
and a prospective long-term follow-up schedule is
expected to give knowledge regarding heredity and vas-
cular co-morbidity. The optimal goal and the major pur-
pose of the study is to reduce vascular morbidity,
disability, cognitive impairment and mortality in young
ischemic stroke patients.
Methods and design
NOR-SYS is intended to be a national multicenter study,
performed by co-operating neurological departments in
Norway. The study was initiated at Haukeland University
Hospital, Bergen, in September 2010. The inclusion period
will be 5 years. NOR-SYS is designed as a three-generation
study with prospective long-term follow-up design. In
addition to a routine cerebro-cardiovascular work-up in-
cluding clinical examination, neuroimaging, cardiac inves-
tigations, and laboratory analyses, all participating patients
and relatives are investigated according to the NOR-SYS
protocol (Figure 1). This includes questionnaires regarding
vascular disease burden in the family, the patient’s medical
history and life styles. In addition, all patients are exam-
ined by transcranial, extracranial, abdominal and periph-
eral ultrasound, arterial stiffness measurements, and
24 hour blood pressure monitoring. Participants with un-
documented but suspected coronary and/or peripheral ar-
terial disease are referred to the Department of Cardiology
and the Department of Vascular Surgery, respectively, for
further appropriate investigations, including cardiac
computertomography-angiography (CCTA) and CT of the
thoracic aorta.
Anthropometric variables, such as height, weight, and
waist-hip ratio are measured and EDTA-blood and serum
samples are collected to a biobank. The patients’ partners
and biological offspring aged ≥18 years are being offered
investigations as shown in Figure 1. Data on medical his-
tory and life styles are collected from the patients’ bio-
logical parents, partners, and offspring by standardized
questionnaires. For deceased first-degree relatives, the pa-
tient will be asked about their cardio-vascular clinical
events and the achieved information will be verified by
medical records and data from the Norwegian Cause of
Death Registry.
NOR-SYS will be carried out in two phases. In the
first, cross-sectional phase, a comprehensive stroke data
base on vascular risk factors, arterial ischemic events,
and clinical and subclinical atherosclerotic disease bur-
den in the study population is being established.
The second, longitudinal phase will constitute long-term
follow-ups, at 5, 10 and 15 years from the time of inclu-
sion for patients and their partners, and at 10 and 20 years
from time of inclusion for offspring. The purpose of the
follow-up is to observe the biological development of ath-
erosclerosis and vascular disease over time, and to
optimize primary and secondary medical prophylaxis. The
complete work-up is shown in Figure 1.
Subject selection
Study participation is offered to all patients with Norwegian
residency aged 15 to 60 years, with radiologically docu-
mented acute cerebral infarction. All study participation
is based on informed written consent. Patients of non-
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western European ethnicity are investigated in agreement
with the NOR-SYS protocol, but are not included in statis-
tical study analyses. Patients with ischemic stroke due to a
traumatic cause or subarachnoidal bleeding are excluded
from study participation. Spouses and partners of included
patients are offered participation as control persons and as
reference persons to participating joint offspring. Parents of
patients and partners are invited to return standardized
questionnaires. All participants are asked for permission to
review their relevant medical records from hospitals, spe-
cialists or general practitioners for verification.
Baseline procedures at study inclusion
A. Oral and written study information and signing of
informed written consent
B. Anamnestic data collection by standardized
questionnaires, including socio-demographic
variables, history of previous vascular disease,
history of vascular risk factors, data on life styles
and nutrition habits, history of other disease,
allergies, recent infections, current medication, and
circumstances around stroke onset.
C. Neurosonology and Duplex/Doppler ultrasound
examinations.
Duplex sonography studies are performed using a
iU22 Philips Medical Systems, Bothell, WA, USA.
Neurosonologists are trained and certified by the
most experienced neurosonologists at Haukeland
University Hospital (LT and UWA) in
collaboration with the University Medical Centre
of Utrecht (RM), The Netherlands. Intra- and
interobserver variability investigations are
performed. Continuous ECG monitoring during
the ultrasound examination is done in order to
perform standardized carotid and femoral IMT-
measurements in the enddiastolic phase of the
Patient 15 - ≤60 years  
Questionnaire (RF, medical history)  
  CT and/or MRI incl. angiography 
TCCS and extracranial duplexsonography 
Duplexsonography abdominal aorta 
Duplexsonography femoral arteries 
Duplexsonography epicardial, intraabdominal 
and subcutaneous adipose tissue 
Peripheral ultrasound (ABI, tonometry) 
Blood pressure measurement, 24h BP 
ECG, TTE and/or TEE 
BMI and Waist-hip-ratio 
Blood samples 
Coronary and aorta CT scan 
Follow-up after 5-10-15 years 
Father              Mother
Questionnaire + Medical information 
(RF, ischemic cerebrovascular, cardiovascular 
and peripheral arterial events) 
Partner
Questionnaire (RF, medical history)  
Extracranial duplexsonography 
Duplexsonography abdominal aorta 
Duplexsonography femoral arteries 
Duplexsonography epicardial, intraabdominal 
and subcutaneous adipose tissue 
Peripheral ultrasound (ABI) 
Blood pressure measurement 
ECG 
BMI and Waist-hip-ratio 
Blood samples
Follow-up after 5-10-15 years 
Offspring ≥18 years  
Questionnaire (RF, ischemic events)  
Extracranial duplexsonography 
Duplexsonography abdominal aorta 
Duplexsonography femoral arteries 
Duplexsonography epicardial, intraabdominal and 
subcutaneous fat 
Peripheral ultrasound (Ancle-Arm-Index) 
Blood pressure measurement 
ECG 
BMI and Waist-hip-ratio 
Blood samples
Follow-up after 10-20 years 
Father              Mother
Questionnaire + Medical information 
(RF, ischemic cerebrovascular, cardiovascular 
and peripheral arterial events) 
Figure 1 NOR-SYS Assessment chart. RF = Risk factors; CT = Computed tomography; MRI = Magnetic resonance imaging; TCCS = Transcranial
color-coded sonography; ABI = Ankle-Brachial Index; ECG = Electrocardiogram; TTE = Transthoracic echocardiography, TEE = Transesophageal
echocardiography; 24 h BP = 24 hour blood pressure monitoring; BMI = Body Mass Index.
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cardiac cycle. Except for cardiac ultrasound
examination, the subject is being placed in supine
position.
a) Transcranial color-coded sonography (TCCS).
The intracranial arteries are systematically
assessed following the protocol established by
Logallo et al. [31]. A 5–1 MHz sector array probe
(iU22 Philips Medical Systems, Bothell, WA,
USA) is used for bilateral insonation of the
sphenoidal segment (M1) and the insular
segments (M2) of the middle cerebral arteries
(MCA) in the axial planes. Peak systolic velocity
(PSV) is measured from M1 origin to distal M2
segments with a 2 mm sample volume, by
stepwise depth decrement, and stepwise optimal
angle correction of Doppler sampling.
b) Carotid artery ultrasonography.
The carotid arteries are examined by use of a
9–3 MHz linear array transducer (iU22 Philips
Medical Systems, Bothell, WA, USA).
b1)Overview, stenoses, hemodynamics and
velocities: For an orientating overview, initial
B-mode scans in transversal and longitudinal
plane are performed to visualize the common
carotid artery (CCA), carotid bifurcation (BIF),
and internal carotid artery (ICA). Segments of
interest are stored as frozen images, or as
video loop. Observation of carotid
atherosclerotic plaques, stenosis, occlusion,
dissection or fibromuscular dysplasia are
noted. In case of stenosis, according to the
international consensus statement [32],
geometric lumen reduction is assessed by
calculation of area reduction in the cross-
sectional plane, using the combination of B-
mode and color flow. Measurement of area
reduction is considered independent from
morphological configurations of the stenosis.
Further, color and power Doppler modes are
used for evaluation of hemodynamic effects in
longitudinal plane, such as orthograde or
retrograde flow, color aliasing phenomenon or
turbulence. Blood flow velocities are measured
using Pulsed-Wave (PW) Doppler under
optimal angle correction. The maximum peak
systolic velocity (PSV) is noted for the distal
CCA, for the carotid bifurcation under
visualization of the proximal ICA, and for the
proximal ICA, of which frozen pictures are
stored.
b2) IMT-measurements: Vertical markers in a
horizontal distance of 10 mm each are used to
define the distal CCA, the bifurcation (BIF),
and the proximal ICA segment in longitudinal
view, using the tip of the flow divider (TFD) as
internal landmark for placement of the second
vertical marker (Figure 2). The CCA segment
is defined 20–10 mm proximally to the TFD,
the BIF segment is defined as 10–0 mm
proximally to the TFD, and the ICA segment
is defined as 0–10 mm distally to the TFD.
Intima-media thickness (IMT) is visualized in
longitudinal view on the far and, if possible, on
the near wall of each segment, to ensure
center position of the scan plane in the artery.
Meijer’s Carotid Arc® (Figure 3) is used for
standardization of the scan angles, performed
at 180º, 150º, 120º and 90º in the right CCA
segment, and at 180º, 210º, 240º, and 270º in
the left CCA segment. IMT-measurements in
BIF and ICA segments are bilaterally
performed at the angle representing the most
significant pathological finding, respectively.
All measurements are performed in the
enddiastolic phase of the cardiac cycle. Frozen
pictures are stored for each measurement.
IMT-analysis is performed by Philips QLAB-
software after completed examination. IMT
measurements are done over a distance of
10 mm for each far wall segment (Figure 2),
and are stored as a mean value. In case of
irregular IMT or presence of plaques,
measurements of the maximum IMT or
plaque thickness are additionally performed.
Due to updated Mannheim Carotid Intima-
Media Thickness Consensus criteria, plaques
are defined as focal IMT measurements
>1.5 mm [33]. Plaque surface is being
evaluated as smooth, irregular or ulcerated.
c Ultrasonographic epicardial adipose tissue (EAT).
EAT measurements are performed by use of a
5–1 MHz sector array transducer (iU22 Philips
Medical Systems, Bothell, WA, USA). The subject
is placed in left lateral decubitus position.
Epicardial fat thickness is measured on the free
wall of the right ventricle from parasternal short-
axis view during end-systole. EAT is defined as
the echo-free space between the outer layer of
the myocardial wall and the visceral layer of the
pericardium [34,35] (Figure 4). The mean of three
maximum value measurements is calculated.
d Ultrasonographic visceral abdominal adipose
tissue (VAT).
VAT measurements are performed by use of a
5–1 MHz curved array transducer (iU22 Philips
Medical Systems, Bothell, WA, USA). All
measurements are performed in longitudinal view
on umbilicus level, and the distance between the
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external face of the rectus abdominis muscle/the
peritoneum and the lumbar spine is used [36]
(Figure 4). All measurements are performed at
the end of expiration and without distortion of
the abdominal cavity due to compression. The
vertebral column is positioned horizontally. VAT
is measured in frontal median position, 10 cm
laterally to the left and 10 cm laterally to the
right for the median position, and the mean value
of these three measurements is calculated.
e Ultrasonographic subcutaneous abdominal
adipose tissue (SAT).
SAT measurement is performed by use of a
9–3 MHz linear array transducer (iU22 Philips
Medical Systems, Bothell, WA, USA).The
transducer is positioned transverse 1 cm above
the umbilicus. SAT is defined as the distance
between the cutis and the external face of the
rectus abdominis muscle tendon plate (linea alba)
(Figure 4), and is measured under maximum
decompression of the skin.
f Abdominal aorta ultrasonography.
The abdominal aorta is examined by use of a
5–1 MHz curved array transducer (iU22 Philips
Medical Systems, Bothell, WA, USA).
Infrarenal vessel lumen is measured in
longitudinal view, and external diameter
measurement is repeated in transversal view.
Infrarenal diameter >30 mm is suspect for
aneurysm and considered for additional
vascular surgical investigations [37].
Hemodynamically significant stenosis is
Figure 2 Ultrasonographic IMT measurement in the proximal ICA (left), the bifurcation (middle) and the distal CCA segment (right) by
QLAB software.
Figure 3 Meijer’s Carotid Arc® (publication with written informed consent by the patient).
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assumed when PSV is ≥ 200 cm/s. Severity of
atherosclerotic lesions is evaluated.
g Femoral artery ultrasonography.
The femoral arteries are examined by use of a
9–3 MHz linear array transducer (iU22 Philips
Medical Systems, Bothell, WA, USA).
Transversal view is used for identification of
the common femoral artery (CFA) and
localisation of the femoral artery bifurcation.
Femoral IMT (fIMT) measurements are
bilaterally performed in longitudinal view over a
distance of 10 mm in the distal CFA (Figure 5)
and in the proximal 10 mm of the superficial
femoral artery (SFA), respectively (Figure 5).
Frozen pictures are stored for each
measurement. As for cIMT, fIMT is analyzed
by Philips QLAB-software after completed
examination, and performed over a distance of
10 mm for each far wall segment and stored as
a mean value. In case of irregular IMT or
presence of plaques, measurements of the
maximum IMT and plaque thickness are
additionally done.
h Ankle Brachial Index (ABI).
ABI is measured after a resting period of at least
5 to 10 minutes by Ultrasonic Doppler Flow
Detector, Model 811-BTS, Parks Medical
Electronics, Inc., Aloha, OR, USA. Bloodpressure
measurements are performed bilaterally in the
radial, the dorsalis pedis, and the posterior tibial
artery. ABI ≤ 0.9 at rest is defined as the cut-off
point for peripheral artery disease (PAD). ABI
0.7-0.9 is considered as mild, 0.4-0.7 as moderate
and <0.4 as severe arterial disease. ABI >1.4 may
be explained by medial sclerosis or other
conditions leading to arterial incompressibility
[38]. Suspect subjects and participants with
known diabetes mellitus are reported to the
respective departments of vascular surgery for
further investigation.
Figure 4 Ultrasonographic epicardial (left), intraabominal visceral (middle) and abdominal subcutaneous adipose tissue (right) in
B-mode ultrasonography.
Figure 5 B-mode ultrasonography and IMT measurement in the distal CFA (left) and the proximal SFA segment (right) performed by
QLAB software.
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D Anthropometric variables, electrocardiography
(ECG), and blood pressure measurements.
Current height and weight are measured and Body
mass index (BMI) is calculated as indicator for
nutrition and body fat. Waist-hip ratio (WHR) is
calculated from the respective circumference
measurements. Systolic and diastolic blood pressures
are measured bilaterally in the subject’s upper arm
after a resting period. ECG is performed in all
actively participating subjects.
E Neuroradiology (patients only).
Routine initial neuroimaging includes a cerebral CT
scan and CT-angiography (CTA), and is performed in
all patients with acute stroke symptoms at hospital
admission. Magnetic resonance imaging (MRI) may be
the method of first choice in some patients. In absence
of contraindications, MRI including axial FLAIR,
MR-angiography (MRA), diffusion-weighted imaging
(DWI) and susceptibility weighted imaging (SWI)
is performed within 24 hours after admission.
Intra- and extracranial artery stenoses are described as
minor (≤50%), moderate (51-70%) and severe
(71-99% maximum actual area reduction (AAR))
or occlusion.
F Arterial stiffness measured by aplanation tonometry
(patients only).
Carotid-femoral pulse wave velocity is measured
using aplanation tonometry (SpygmoCor, AtCor
medical, West Ryde, Australia) operated by a
trained technician following a standardized
program with inborn quality control assessment.
Pulse waves from the carotid and femoral arteries
are obtained with the tonometer and the pulse
wave velocity is calculated taking the distance
between the two measure points into account.
From the carotid pulse wave, central (aortic)
blood pressure is estimated.
G Ambulatory blood pressure monitoring.
Twenty-four hour ambulatory blood pressure
measurement is performed using a non-invasive
ambulatory blood pressure monitor Diasys
Integra II (Novacor, Cedex, France), set to
auscultatory mode. The device is mounted on the
non-dominant arm with an appropriately sized
cuff, and the patients are instructed to relax their
arm when readings are initiated. Blood pressure
is pre-set to be measured every 20 minutes
during daytime and every 30 minutes during
night-time, giving an average of 78 measurements
per 24 hours. Daytime is defined as the fixed
period between 7 a.m. and 22 p.m.. The
recording is accepted when > 70% of the
measurements are technically valid, and
otherwise will be repeated.
H CCTA including CT of the thoracic aorta (patients
only).
CCTA and CT of the thoracic aorta is performed in
those patients found to have plaques in the femoral
arteries and/or pathological ABI. For ECG-triggered
CT-scanning, a Siemens dual FLASH scanner
(Siemens Somatom Definition FLASH; Erlangen,
Germany) is applied. Due to administration of I-
contrast agents, patients with reduced glomerular
filtration rate (GFR < 30 mL/min/1.73 m2) are
excluded. Calcium scoring of coronary arteries is
assessed before administration of intravenous
contrast, whereas, the lumen and wall of the
coronary arteries as well as the occurrence of aorta
pathology is evaluated after intravenous contrast
administration.
I Study of biomarkers and genetic analyses.
Samples of serum and EDTA-plasma are collected,
processed, coded and stored at −80°C until
analyzation for each participating subject. Analyses
are scheduled after completion of the 5-years
inclusion period. Biomarkers to be investigated will be
determined at the time of analyses according to the
most relevant biomarkers known at that time point.
GWAS, exone sequencing or any newer technology,
relevant and feasible at the time of genetic analyses,
will be applied.
Primary and secondary prevention strategies
Additionally to stroke treatment and secondary prevention
in the patient population, all subjects are being evaluated
concerning the presence and severity of established clin-
ical and sub-clinical cardiovascular disease and modifiable
vascular risk factors. An evaluation sheet is given to all pa-
tients at discharge, issues where improvement is recom-
mended are pointed out and intervention is initiated as
soon as possible during hospital stay. For family members,
a short report is being sent to their respective general
practitioner, in which clinical and anamnestic results are
discussed and recommendations for intervention or fur-
ther investigation are given. A modified Essen Stroke Risk
Scale is applied for all participants [39].
Prospective follow-up
During a standardized telephone interview one week
after discharge performed by a study nurse, patients are
asked to evaluate the information they received
concerning their stroke, investigation results, and indi-
vidual vascular risk factors, as well as their hospital stay
in general. Three months follow-up is performed at the
out-patient clinic and includes standardized question-
naires concerning recurrent ischemic events, seizures,
pain, cognitive function, psychological disorders, toler-
ability of medication, quality of life, employment/
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education after the stroke, sick leave, as well as changes
with respect to life styles and modifiable risk factors
after discharge. Clinical and functional scoring by
NIHSS, mRS, and Barthel index are performed, and
weight and blood pressure measurements are repeated.
One-year follow-up is performed by telephone interview
as short standardized questionnaire update on changes
concerning modifiable risk factors.
For long-term follow-up, examinations C. a-h and D.
will be repeated after 5, 10 and 15 years or after 10 and
20 years from inclusion regarding patients and partners
or their offspring, respectively.
Study endpoints
Primary endpoints are death and documented cerebral,
coronary and/or peripheral arterial events. Secondary
endpoints are the long-term development or progression
of atherosclerosis and the failure of therapeutic goal
achievement (tobacco cessation, well-regulated blood-
pressure, dyslipidemia and diabetes mellitus, and normal
weight or slight overweight). Data validation will be done
by medical record information.
Statistics
All obtained data are registered in the NOR-SYS Re-
search Registry. Statistical analyses are performed by’
STATA/SE for Windows’and ‘R’ in cooperation with a
biostatistician.
Discussion
Long-term follow-up studies of young stroke patients have
shown high mortality and vascular morbidity compared to
healthy controls [6-10,40]. Hence, a prospective cohort
follow-up based on thorough investigation of clinical and
sub-clinical vascular disease and risk factors is necessary
in order to achieve a better long-term outcome.
Ultrasound imaging has been proved to be a sensitive
and cost-effective method for the detection of arterial
vessel disease in major arteries [16], as well as for the
evaluation of adipose tissue [35,41]. For this reason,
ultrasound was chosen as the predominating tool for the
investigations in the NOR-SYS protocol. IMT increases
are dependent on age, sex and cardiovascular risk [42].
However, the increase and prevalence of atherosclerotic
lesions vary among different anatomical segments.
Moreover, increased IMT has repeatedly been associated
with cardiovascular risk factors and the incidence of car-
diovascular events [19,43], and has been validated as a
surrogate marker of atherosclerosis [44,45]. Atheroscler-
otic lesions are not distributed circumferentially, but de-
velop asymmetrically [46], and their prevalence varies in
the different artery segments [47]. In our study, Meijer’s
Carotid Arc® is used for standardized imaging at defined
angles [47,48], and cIMT and plaque measurements are
aquired bilaterally in three carotid segments: the distal
CCA, the bifurcation and the proximal ICA [47]. We
suppose that this approach will improve the individual risk
classification, as recently suggested [49]. It has also been
suggested that the presence of carotid artery plaques may
be even more representative for CVD prediction than in-
creased cIMT itself [50]. Hence, plaque measurements are
performed in addition to the standardized IMT measure-
ments at all three carotid sites, if present.
Atherosclerosis is a systemic disease, and lesions are
often to be found in several locations of the vasculature,
such as in the peripheral arteries. Intermittent claudica-
tion is a frequent condition in western European popula-
tions [51,52] and associated with symptomatic CAD and
cerebrovascular events [53,54]. Acute death due to PAD
has been shown in 9% [40], compared to 45% and 42%
due to cerebrovascular and coronary death, respectively
[55]. The CFA has been reported as the segment most
prone to IMT increase and plaque formation [42] com-
pared to the SFA and the carotids. CFA IMT has beyond
that been related to coronary angiographic [56] and
echocardiographic parameters [57]. It is considered suit-
able for long-term observations concerning the natural
development of atherosclerosis in healthy participants,
and for the observation of treatment effects in a partici-
pant group requiring intervention [42]. For these rea-
sons, IMT measurements are additionally performed
bilaterally in the distal CFA and the proximal SFA seg-
ment, and included in study analyses. Atherosclerosis in
the abdominal aorta is leading to aortic stenoses and
PAD. Abdominal aortic aneurysms are also considered
to be a manifestation of advanced atherosclerosis [58],
and are frequently observed in patients with carotid
stenoses, cardiovascular events and PAD [59]. Therefore,
in NOR-SYS the abdominal aorta is evaluated with re-
spect to atherosclerotic lesions, stenoses, and aneurysms.
The ABI is performed in all participants as it is a well-
established tool in investigation for peripheral artery dis-
ease and adds valuable information to vascular risk pre-
diction [60,61].
Standard screening for a cardiac embolic source, in-
cluding 24 hour heart rhythm registration and echocar-
diography is carried out in order to diagnose left
ventricular hypertrophy, abnormal left ventricular geom-
etry, and dilated left atrium as they are well-known pre-
dictors of stroke, both in the general as well as in the
hypertensive population [62]. Blood pressure is mea-
sured after hospital discharge as an ambulatory 24-hour
measurement as it has been proven to be closer associ-
ated with cardiovascular target organ damage and inci-
dent cardiovascular events than clinic pressure [63].
Ambulatory blood pressure measurements identify
hypertension more accurately than clinic blood pressure
measured during an acute stroke.
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Measurement of arterial stiffness by carotid-femoral
pulse wave velocity by aplanation tonometry may be use-
ful in identifying arterial disease which is not captured
by routine carotid ultrasound visualization [64].
NOR-SYS includes CCTA and CT of the thoracic
aorta because of the well-known association between
peripheral and coronary disease [65]. In addition, aortic
arch atheroma or other wall disease of the ascending
aorta or the aortic arch might cause the index-stroke or
recurrent stroke [66].
Obesity is an increasingly prevalent disorder [67]
which is associated with atherosclerosis and cardiovascu-
lar disease. Particularily abdominal obesity has been as-
sociated with metabolic syndrome [68], pre-clinical
atherosclerosis [69], cardiovascular events [70] and
mortality [70].
Epicardial adipose tissue (EAT) has its embryologic
origin in common with mesenteric and omental fat, and
all these are accordingly classified as visceral adipose tis-
sue (VAT) [71,72]. Associations between VAT and cIMT
[73], metabolic syndrome [74,75] and cardiovascular dis-
ease [76,77] have been reported in several studies. Re-
lease of free fatty acids due to the proximity to the
portal circulation leading to direct lipotoxicity [78,79],
and release of pro-inflammatory and pro-atherogenic cy-
tokines and hormones with impact on endothelial func-
tion [80,81] are related issues. The accumulation of VAT
has therefore been found to be an independent vascular
risk factor, even within the normal range of BMI [82].
Accordingly, the anatomical relationship of EAT to the
heart is providing local interaction with modulation of
the coronary arteries and the myocardium, which may
subsequently affect cardiac function and morphology
[83-85]. On the other hand, subcutaneous adipose tissue,
which is a non-portal fat type with less metabolic activity
[86], has previously shown only a weak relationship to
increased cIMT [73]. Its evaluation related to the
amount of VAT and anthropometric parameters is as-
sumed to be relevant for risk prediction and for that rea-
son included in NOR-SYS. Anthropometric parameters
such as BMI and WHR are simply applicable clinical
tools and widely used in obesity evaluation. They are as
well associated with ultrasonographic visceral adipose
tissue measurements [41,87], and applied in NOR-SYS.
In conclusion, the major objective of NOR-SYS is the
standardized gathering of anamnestic, clinical, and bio-
logical data concerning life styles, medical history, and
clinical and subclinical vascular disease at several sites of
the vasculature including body fat composition and an-
thropometric measurements in young ischemic stroke
patients and their families. Standardized questionnaires
and standardized ultrasound examinations combined
with detailed clinical data are assumed to increase the
precision in diagnostics and risk estimation, and
generate a solid basis of decision-making concerning
secondary prophylaxis after acute ischemic stroke.
Further investigation and evaluation of vascular risk
factors and sub-clinical artery wall disease in young is-
chemic stroke patients’ family members provide a plat-
form for primary prophylaxis and early intervention.
NOR-SYS aims to reduce co-morbidity, disability, re-
current stroke, cognitive impairment and mortality in
young patients with acute ischemic stroke. We expect
that a comprehensive work-up and long-term observa-
tion, combined with biological, genetical and clinical in-
formation gathered from three family generations, will
give the opportunity to improve our basic knowledge
concerning preclinical atherosclerosis in families with a
vascular disease burden.
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